A summary of industry trends from July 11, 2025, noting the Humira patent expiration, Johnson & Johnson's consistency, and Medtronic's dividend increases.
2 reports, 2 independent
Updated Sep 25
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A summary of industry trends from July 11, 2025, noting the Humira patent expiration, Johnson & Johnson's consistency, and Medtronic's dividend increases.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Medtronic plc
medical device company
Related events
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.
- AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.
Coverage
Newest first; wire copies grouped- aol.com
- Motley FoolWhat Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired,